During the first 3 months of PAP-guided HF therapy prior to SGLT2 initiation, as well as 6 months after initiation of SGLT2-I therapy, hemodynamic monitoring of diastolic, mean, and systolic PAP revealed stable pressures and no significant change in any value (3 months prior to SGLT2-I: PAP diastolic: 22 ± 7 mmHg; PAP mean: 32 ± 9 mmHg; PAP systolic 46 ± 12 mmHg, 6 months post-SGLT2-I: PAP diastolic: 21 ± 5 mmHg, p3 = 1.000; PAP mean: 31 ± 7 mmHg, p3 = 1.000; PAP systolic 45 ± 9 mmHg, p3 = 1.000, Table 2). The gene discussed is SLC5A2; the disease is hydrops fetalis.